{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:23:56Z","timestamp":1790767436733,"version":"4.1.0"},"reference-count":115,"publisher":"SAGE Publications","issue":"9-10","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:p>\n                    Duchenne muscular dystrophy (DMD) is a serious, rare genetic disease, affecting primarily boys. It is caused by mutations in the\n                    <jats:italic toggle=\"yes\">DMD<\/jats:italic>\n                    gene and is characterized by progressive muscle degeneration that results in loss of function and early death due to respiratory and\/or cardiac failure. Although limited treatment options are available, some for only small subsets of the patient population, DMD remains a disease with large unmet medical needs. The adeno-associated virus (AAV) vector is the leading gene delivery system for addressing genetic neuromuscular diseases. Since the gene encoding the full-length dystrophin protein exceeds the packaging capacity of a single AAV vector, gene replacement therapy based on AAV-delivery of shortened, yet, functional microdystrophin genes has emerged as a promising treatment. This article seeks to explain the rationale for use of the accelerated approval pathway to advance AAV microdystrophin gene therapy for DMD. Specifically, we provide support for the use of microdystrophin expression as a surrogate endpoint that could be used in clinical trials to support accelerated approval.\n                  <\/jats:p>","DOI":"10.1089\/hum.2022.190","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T01:32:47Z","timestamp":1674610367000},"page":"404-415","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":34,"title":["Microdystrophin Expression as a Surrogate Endpoint for Duchenne Muscular Dystrophy Clinical Trials"],"prefix":"10.1177","volume":"34","author":[{"given":"Jeffrey S.","family":"Chamberlain","sequence":"first","affiliation":[{"name":"Department of Neurology, Sen. Paul D. Wellstone Muscular Dystrophy Specialized Research Center, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7924-8604","authenticated-orcid":false,"given":"Melissa","family":"Robb","sequence":"additional","affiliation":[{"name":"Robb Consulting (contractor of REGENXBIO, Inc.), Columbia, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Braun","sequence":"additional","affiliation":[{"name":"AFMTelethon, Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy J.","family":"Brown","sequence":"additional","affiliation":[{"name":"Solid Biosciences, Inc., Charlestown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Danos","sequence":"additional","affiliation":[{"name":"REGENXBIO, Inc., Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Ganot","sequence":"additional","affiliation":[{"name":"Solid Biosciences, Inc., Charlestown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Gonzalez-Alegre","sequence":"additional","affiliation":[{"name":"Spark Therapeutics, Inc., Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Hunter","sequence":"additional","affiliation":[{"name":"REGENXBIO, Inc., Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"McDonald","sequence":"additional","affiliation":[{"name":"University of California Davis Medical Center, Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Morris","sequence":"additional","affiliation":[{"name":"Solid Biosciences, Inc., Charlestown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Tobolowsky","sequence":"additional","affiliation":[{"name":"Hyman, Phelps &amp; McNamara, P.C. (former contractor of REGENXBIO, Inc.), Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn R.","family":"Wagner","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche, Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Ziolkowski","sequence":"additional","affiliation":[{"name":"Former contractor of REGENXBIO, Inc., Rockville, Maryland, USA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Neurology, Biomedical Sciences, and Biomedical, Biological &amp; Chemical Engineering, University of Missouri, Columbia, Missouri, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00248-3"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/428143"},{"issue":"4","key":"e_1_3_5_4_2","first-page":"179","article-title":"Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies","volume":"39","author":"Hoffman EP.","year":"2020","unstructured":"Hoffman EP. Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies. Acta Myol, 2020; 39(4):179\u2013186.","journal-title":"Acta Myol"},{"key":"e_1_3_5_5_2","unstructured":"National Institute for Neurological Disorders and Stroke. Muscular Dystrophy: Hope Through Research. 2013. Available from: https:\/\/www.ninds.nih.gov\/Disorders\/Patient-Caregiver-Education\/Hope-Through-Research\/Muscular-Dystrophy-Hope-Through-Research [Last accessed: October 5 2022]."},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2016.07.020"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01862-w"},{"key":"e_1_3_5_8_2","unstructured":"Darras BT Urion DK Ghosh PS. Dystrophinopathies. 2000 [Updated 2022 Jan 20]. In: GeneReviews\u00ae. (Adam MP Everman DB Mirzaa GM et al. eds.) University of Washington: Seattle (WA); 1993\u20132022. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1119 [Last accessed: October 5 2022]."},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200555"},{"key":"e_1_3_5_10_2","unstructured":"FDA Guidance for Industry: Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment. February 2018. Available from: https:\/\/www.fda.gov\/media\/92233\/download [Last accessed: October 5 2022]."},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.07.011"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0012-9"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.012"},{"key":"e_1_3_5_14_2","unstructured":"21U.S.C. \u00a7 506(c)(1)(A) of the Federal Food Drug & Cosmetic Act."},{"key":"e_1_3_5_15_2","unstructured":"21U.S.C. \u00a7 356(c)(2)(A) of the Federal Food Drug & Cosmetic Act and 21 CFR 314.510 and 601.41."},{"key":"e_1_3_5_16_2","unstructured":"21U.S.C. \u00a7 356(c)(3)(A) of the Federal Food Drug & Cosmetic Act and 21 CFR 314.510 314.530 601.41 and 601.43."},{"key":"e_1_3_5_17_2","unstructured":"FDA news release: FDA approves drug to treat Duchenne muscular dystrophy. February 9 2017. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-drug-treat-duchenne-muscular-dystrophy [Last accessed: October 5 2022]."},{"key":"e_1_3_5_18_2","unstructured":"FDA Guidance for Industry: Expedited Programs for Serious Conditions\u2014Drugs and Biologics. May 2014. Available from: https:\/\/www.fda.gov\/media\/86377\/download [Last accessed: November 21 2022]."},{"key":"e_1_3_5_19_2","unstructured":"Emflaza (deflazacort) Prescribing Information. June 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208684s005 208685s005lbl.pdf [Last accessed: October 5 2022]."},{"key":"e_1_3_5_20_2","unstructured":"FDA. Final Rule New Drug Antibiotic and Biological Drug Product Regulations; Accelerated Approval (57 FR 58942 58944 December 11 1992)."},{"key":"e_1_3_5_21_2","unstructured":"FDA Center for Drug Evaluation and Research. Summary Review Application Number:. 206488. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/206488_summary%20review_Redacted.pdf [Last accessed: October 5 2022]."},{"key":"e_1_3_5_22_2","unstructured":"FDA Center for Drug Evaluation and Research. Summary Review Application Number:. 211970. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211970Orig1s000SumR.pdf [Last accessed: October 5 2022]."},{"key":"e_1_3_5_23_2","unstructured":"FDA Center for Drug Evaluation and Research. Summary Review Application Number:. 212154. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/212154Orig1s000SumR.pdf [Last accessed: October 5 2022]."},{"key":"e_1_3_5_24_2","unstructured":"FDA Center for Drug Evaluation and Research. Summary Review Application Number:. 213026. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/213026Orig1s000SumR.pdf [Last accessed: October 5 2022]."},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2006.05.010"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.122.4.809"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/210797"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddw123"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddm158"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0302-253"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.01.002"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/343180a0"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/B0-44-306557-8\/50109-X"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2014.06.224"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1159\/000517411"},{"key":"e_1_3_5_36_2","unstructured":"Butterfield RJ. One year data from ambulatory boys in a phase 1b open-label study of fordistrogene movaparvovec (PF-06939926) for Duchenne muscular dystrophy. In: Presented as part of Muscular Dystrophy Association Clinical and Scientific Conference March 2022 Nashville TN."},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1439"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.283"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddv310"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1484"},{"key":"e_1_3_5_41_2","unstructured":"FDA Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review Application Number:. 206488. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/206488Orig1s000ClinPharmR.pdf [Last accessed: October 5 2022]."},{"key":"e_1_3_5_42_2","unstructured":"FDA Center for Drug Evaluation and Research. Medical Review Application Number:. 206488. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/206488Orig1s000MedR.pdf [Last accessed: October 5 2022]."},{"issue":"4","key":"e_1_3_5_43_2","first-page":"498","article-title":"The molecular basis for Duchenne versus Becker muscular dystrophy: Correlation of severity with type of deletion","volume":"45","author":"Koenig M","year":"1989","unstructured":"Koenig M, , Beggs AH, , Moyer M, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: Correlation of severity with type of deletion. Am J Hum Genet, 1989; 45(4):498\u2013506.","journal-title":"Am J Hum Genet"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36612"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/364725a0"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1093-130"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/3.6.919"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/4.8.1251"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/4.8.1245"},{"key":"e_1_3_5_50_2","first-page":"251","article-title":"Dystrophin levels required for correction of Duchenne muscular dystrophy","volume":"7","author":"Chamberlain JS.","year":"1997","unstructured":"Chamberlain JS. Dystrophin levels required for correction of Duchenne muscular dystrophy. Basic Appl Myol, 1997; 7:251\u2013255.","journal-title":"Basic Appl Myol"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.240335297"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(98)00251-8"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.07.025"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2022.181"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1085"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/jor.20781"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.154"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.28"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2012.05.002"},{"key":"e_1_3_5_60_2","unstructured":"Hakim CH Kodippili K Jenkins G et al. AAV micro-dystrophin therapy ameliorates muscular dystrophy in young adult Duchenne muscular dystrophy dogs for up to thirty months following injection. Mol Ther2018;26 (5S1):5 (abstract)."},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00335-011-9382-y"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.94"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16105"},{"key":"e_1_3_5_64_2","unstructured":"Abmayr S Chamberlain J. The structure and function of dystrophin. In: The Molecular Mechanisms of Muscular Dystrophies. (Winder SJ. ed.) Landes Biosciences: Georgetown; 2006; pp. 14\u201334."},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.43.28419"},{"key":"e_1_3_5_66_2","first-page":"54","article-title":"Exploring the molecular basis for variability among patients with Becker muscular dystrophy: Dystrophin gene and protein studies","volume":"49","author":"Beggs AH","year":"1991","unstructured":"Beggs AH, , Hoffman EP, , Snyder JR, et al. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: Dystrophin gene and protein studies. Am J Hum Genet, 1991; 49:54\u201367.","journal-title":"Am J Hum Genet"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(94)00397-1"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.134.4.873"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(92)80019-D"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-2126(00)00132-5"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.135.3.661"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.45.28771"},{"key":"e_1_3_5_73_2","first-page":"31","article-title":"A multiple site, side binding model for the interaction of dystrophin with F-actin","volume":"52","author":"Ervasti JM","year":"1997","unstructured":"Ervasti JM, , Rybakova IN, , Amann KJ. A multiple site, side binding model for the interaction of dystrophin with F-actin. Soc Gen Physiol Ser, 1997; 52:31\u201344.","journal-title":"Soc Gen Physiol Ser"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.150.5.1209"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/11.9.1095"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/77923"},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.45.27305"},{"key":"e_1_3_5_78_2","first-page":"431","article-title":"The WW domain of dystrophin requires EF-hands region to interact with beta-dystroglycan","volume":"380","author":"Rentschler S","year":"1999","unstructured":"Rentschler S, , Linn H, , Deininger K, et al. The WW domain of dystrophin requires EF-hands region to interact with beta-dystroglycan. J Biol Chem, 1999; 380:431\u2013442.","journal-title":"J Biol Chem"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(92)81265-N"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115909"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddh087"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.134.1.93"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/0387-7604(93)90069-K"},{"key":"e_1_3_5_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(02)00362-5"},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2022.180"},{"key":"e_1_3_5_86_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000958"},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2017.06.006"},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.122.011161"},{"key":"e_1_3_5_89_2","unstructured":"Solid Biosciences. Solid Biosciences Reports Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg\/kg Cohort. March 15 2021. Available from: https:\/\/www.solidbio.com\/about\/media\/press-releases\/solid-biosciences-reporssts-efficacy-and-safety-data-from-the-ongoing-ignite-dmd-clinical-trial-and-resumption-of-patient-dosing-in-the-2e14-vg-kg-cohort [Last accessed: October 5 2022]."},{"key":"e_1_3_5_90_2","unstructured":"Solid Biosciences. Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I\/II Clinical Trial of SGT-001. September 27 2021. Available from: https:\/\/www.solidbio.com\/about\/media\/press-releases\/solid-biosciences-reports-1-5-year-data-from-patients-in-the-ongoing-ignite-dmd-phase-i-ii-clinical-trial-of-sgt-001 [Last accessed: October 5 2022]."},{"key":"e_1_3_5_91_2","unstructured":"Solid Biosciences. Solid Biosciences Reports Fourth Quarter and Full-Year2021 Financial Results and 2-Year Efficacy and Safety Data from the Ongoing Phase I\/II IGNITE DMD Clinical Trial of SGT-001. March 14 2022. Available from: https:\/\/www.solidbio.com\/about\/media\/press-releases\/solid-biosciences-reports-fourth-quarter-and-full-year-2021-financial-results-and-2-year-efficacy-and-safety-data-from-the-ongoing-phase-i-ii-ignite-dmd-clinical-trial-of-sgt-001 [Last accessed: October 5 2022]."},{"key":"e_1_3_5_92_2","unstructured":"Pfizer press release: Pfizer's New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study. May 15 2020. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-new-phase-1b-results-gene-therapy-ambulatory-boy [Last accessed: October 5 2022]."},{"key":"e_1_3_5_93_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84863-w"},{"key":"e_1_3_5_94_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195850"},{"key":"e_1_3_5_95_2","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2016.28"},{"issue":"1","key":"e_1_3_5_96_2","first-page":"158","article-title":"Frameshift deletions of exons 3\u20137 and revertant fibers in Duchenne muscular dystrophy: Mechanisms of dystrophin production","volume":"56","author":"Winnard AV","year":"1995","unstructured":"Winnard AV, , Mendell JR, , Prior TW, et al. Frameshift deletions of exons 3\u20137 and revertant fibers in Duchenne muscular dystrophy: Mechanisms of dystrophin production. Am J Hum Genet, 1995; 56(1):158\u2013166.","journal-title":"Am J Hum Genet"},{"key":"e_1_3_5_97_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.31.11.843"},{"key":"e_1_3_5_98_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002891"},{"key":"e_1_3_5_99_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031937"},{"key":"e_1_3_5_100_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/3.10.1725"},{"key":"e_1_3_5_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2014.01.009"},{"key":"e_1_3_5_102_2","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2008.071042"},{"key":"e_1_3_5_103_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015286"},{"key":"e_1_3_5_104_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25951"},{"key":"e_1_3_5_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2016.11.011"},{"key":"e_1_3_5_106_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1073"},{"key":"e_1_3_5_107_2","doi-asserted-by":"publisher","DOI":"10.37421\/jch.2020.11.553"},{"issue":"89","key":"e_1_3_5_108_2","first-page":"51586","article-title":"Tissue triage and freezing for models of skeletal muscle disease","author":"Meng H","year":"2014","unstructured":"Meng H, , Janssen PM, , Grange RW, et al. Tissue triage and freezing for models of skeletal muscle disease. J Vis Exp, 2014;(89):51586.","journal-title":"J Vis Exp"},{"key":"e_1_3_5_109_2","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12785"},{"key":"e_1_3_5_110_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-021-00300-7"},{"key":"e_1_3_5_111_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlab088"},{"key":"e_1_3_5_112_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-180357"},{"issue":"1","key":"e_1_3_5_113_2","first-page":"40","article-title":"Challenges of interpreting dystrophin content by Western blot","volume":"15","author":"Schnell FJ","year":"2019","unstructured":"Schnell FJ, , Frank DE, , Fletcher S, et al. Challenges of interpreting dystrophin content by Western blot. US Neurol, 2019; 15(1):40\u201346.","journal-title":"US Neurol"},{"key":"e_1_3_5_114_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.107.162982"},{"key":"e_1_3_5_115_2","unstructured":"FDA Draft Guidance for Industry: Rare Diseases: Common Issues in Drug Development. January 2019. Available from: https:\/\/www.fda.gov\/media\/119757\/download [Last accessed: October 5 2022]."},{"key":"e_1_3_5_116_2","unstructured":"FDA Guidance for Industry: Long Term Follow-Up After Administration of Human Gene Therapy Products. January 2020. Available from: https:\/\/www.fda.gov\/media\/113768\/download [Last accessed:October 5 2022]."}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2022.190","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2022.190","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2022.190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:56:57Z","timestamp":1777449417000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2022.190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":115,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1089\/hum.2022.190"],"URL":"https:\/\/doi.org\/10.1089\/hum.2022.190","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}